Business Context and Reporting Period
This Form 8-K Current Report was filed by Transdel Pharmaceuticals, Inc. on June 26, 2011. The filing discloses a voluntary petition for reorganization relief under Chapter 11 of the United States Bankruptcy Code filed in the U.S. Bankruptcy Court for the Southern District of California (Case No. 11-10497-11). The Company continues to operate as a debtor-in-possession.
Key Financial Metrics and Obligations
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or operating margins. However, it discloses specific financial obligations triggered by the bankruptcy filing:
- Accelerated Debt: The Chapter 11 filing triggered an event of default under a Senior Convertible Promissory Note dated April 5, 2010. The total principal and accrued interest immediately due and payable is $1,091,849.
- Lease Obligations: The filing created an event of default under the Company's operating leases.
- Enforcement Status: Enforcement rights for both the Note and lease defaults are currently stayed under the Bankruptcy Code.
Material Changes and Asset Sale
Concurrent with the bankruptcy filing, the Company entered into an Asset Purchase Agreement with Cardium Healthcare, Inc. (a wholly-owned subsidiary of Cardium Therapeutics, Inc.) to sell substantially all of its assets. Key terms include:
- Consideration: Up to 6 million shares of Cardium Therapeutics, Inc. common stock, subject to adjustment based on the closing price of the stock.
- Escrow Provision: Additional shares may be released from escrow upon the successful timely registration of the Company's principal product candidate, TDLP-110, under section 505(b)(2) of the U.S. Food, Drug and Cosmetic Act.
- Restrictions: All stock received will be restricted, with limitations on liquidation imposed by the agreement and SEC Rule 144.
Guidance, Risks, and Contingencies
The consummation of the asset sale is subject to several material contingencies and risks:
- Court Approval: The sale requires approval by the Bankruptcy Court via a Sale Order. Despite a request for a private sale, the transaction may be subject to auction procedures and higher bids.
- Termination Rights: The Purchaser may terminate the agreement if the Company breaches representations or fails to obtain necessary court orders by agreed dates.
- Conditions Precedent: Closing is contingent on the accuracy of representations, material compliance with obligations, and adherence to specified deadlines.
Investor Verification Checklist
- Verify the status of the Bankruptcy Court's approval of the Asset Purchase Agreement and whether the sale was conducted as a private transaction or via auction.
- Confirm the final number of Cardium Therapeutics shares issued to the Company and the valuation at closing.
- Monitor the progress of the TDLP-110 product registration to determine if escrow shares will be released.
- Review the treatment of the $1,091,849 convertible note and lease defaults within the Chapter 11 reorganization plan.
- Check for any subsequent filings regarding the termination of the Asset Purchase Agreement.